Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

  title={Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia},
  author={Bryan L. Roth and Douglas J. Sheffler and Wesley K. Kroeze},
  journal={Nature Reviews Drug Discovery},
Most common central nervous system disorders — such as depression, bipolar disorder and schizophrenia — seem to be polygenic in origin, and the most effective medications have exceedingly complex pharmacologies. Attempts to develop more effective treatments for diseases such as schizophrenia and depression by discovering drugs selective for single molecular targets (that is, 'magic bullets') have, not surprisingly, been largely unsuccessful. Here we propose that designing selectively non… 

Novel Drugs and Therapeutic Targets for Severe Mood Disorders

Several promising drugs and drug targets for mood disorders using one or both of these approaches are described, including antidepressant and mood-stabilizing agents targeting common intracellular pathways of known monoaminergic agents and lithium/mood stabilizers.

Multifunctional drugs with different CNS targets for neuropsychiatric disorders

In this review, an overview of therapeutic strategies and novel investigative drugs discovered or developed in the authors' own and other laboratories, that address multiple CNS etiological targets associated with an array of neuropsychiatric disorders are offered.

Potential Molecular and Cellular Mechanism of Psychotropic Drugs

  • M. SeoE. ScarrC. LaiB. Dean
  • Psychology
    Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology
  • 2014
This review has focused on recent findings on the molecular mechanism affected by antipsychotic, mood stabilizing and antidepressant drugs at the levels of epigenetics, intracellular signalling cascades and microRNAs.

Targeting ligand-gated ion channels in neurology and psychiatry: is pharmacological promiscuity an obstacle or an opportunity?

Developing promiscuity maps of approved neuro-pharmaceuticals will provide therapeutic class-based templates against which candidate compounds can be screened and compounds previously rejected in traditional screens due to poor specificity could be reconsidered in this framework.

Polypharmacology of dopamine D1-like receptor antagonists

The polypharmacological profile and potential therapeutic application of dopamine D1-like receptor antagonists and their applications in drug discovery for complex multifactorial diseases are reviewed.



Novel directions in antipsychotic target identification using gene arrays.

This multi-parameter high throughput screening (MPHTS(SM) approach evaluates the mRNA expression pattern of cultured cells exposed to candidate compounds that normalize genes altered in schizophrenia may better address its underlying causes.

BMY 14802, a Sigma Receptor Ligand for the Treatment of Schizophrenia

The results of an uncontrolled, multicenter safety and efficacy study of patients with acute exacerbations of schizophrenia treated with BMY 14802 report no significant improvement in psychiatric symptoms, as measured by the total Brief Psychiatric Rating Scale scores or Clinical Global Improvement.

A historical perspective of clozapine.

  • H. Hippius
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 1999
The history of clozapine's development, from its discovery in 1958 to its current position as the "gold standard" therapy for treatment-resistant schizophrenia, is outlined.

H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs

It is recommended that the next generation of atypical antipsychotic drugs be screened to avoid H1-histamine receptors, which are known to induce weight gain with chronic use.

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.

The NK(3) and 5-HT(2A/2C) antagonists showed evidence of efficacy in the treatment of schizophrenia and schizoaffective disorder, and a smaller number of patients receiving placebo was permitted to test the efficacy of the four novel compounds.

Finding the Intracellular Signaling Pathways Affected by Mood Disorder Treatments

Discovering risperidone: the LSD model of psychopathology

In the 1970s and 1980s, Janssen Pharmaceutica Research, which had a broad interest in central nervous system disorders and nurtured intellectual freedom, developed original, and at times heretical, concepts, which enabled the discovery of the antipsychotic risperidone, a unique full antagonist of the interoceptive effects of LSD.

Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology

The results support the hypothesis that the unique actions of aripiprazole in humans are likely a combination of ‘functionally selective’ activation of D2 (and possibly D3)-dopamine receptors, coupled with important interactions with selected other biogenic amine receptors—particularly 5-HT receptor subtypes (5-HT1A, 5- HT2A).